Vir Biotechnology, Inc. (VIR) Stock Analysis
Healthcare · Biotechnology · NasdaqGS
Vir Biotechnology, Inc. (VIR) posted $68.56M in revenue for fiscal 2025 (down 7.6% year over year), with a net loss of $437.99M, and has compounded revenue about -2.1%/yr over five years, per its SEC filings.
Data last refreshed August 2, 2026 from SEC filings · how we compute this
The analyst's take on Vir Biotechnology, Inc.
Vir Biotechnology, Inc. has grown revenue from $2.71M to $68.56M over the last 9 fiscal years, compounding about -2.1% a year. The most recent year was down 7.6%, so growth has cooled from its longer-run pace.
Net margin sits at -638.9%, up 64.5 points year over year on a 100% gross margin.
The one thing worth a second look in the filings is currently unprofitable.
Synthesised from Vir Biotechnology, Inc.'s SEC filings — descriptive, not advice. Ask the analyst your own question →
Vir Biotechnology, Inc. revenue & earnings — last 9 fiscal years
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.71M | $10.67M | $8.09M | $76.37M | $1.10B | $1.62B | $86.18M | $74.20M | $68.56M |
| Gross profit | — | — | — | — | $1.03B | $1.47B | $83.42M | $73.36M | $68.53M |
| Net income | $-69.85M | $-115.88M | $-174.68M | $-298.67M | $528.58M | $515.84M | $-615.06M | $-521.96M | $-437.99M |
| Net margin | -2579.5% | -1086.3% | -2159.0% | -391.1% | 48.3% | 31.9% | -713.7% | -703.4% | -638.9% |
Source: Vir Biotechnology, Inc. SEC filings (10-K).
Vir Biotechnology, Inc.: 1 potential red flag in the filings
Patterns in the filed statements worth a second look — computed and cited, not AI guesswork, and not a signal to sell. The kind of thing that hides in a 10-K.
- Currently unprofitableThe latest fiscal year was a net loss (net margin -638.9%).
Explore 9 years of Vir Biotechnology, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track VIR in your portfolio →
Vir Biotechnology, Inc. financial history by metric
Compare Vir Biotechnology, Inc. with peers
About Vir Biotechnology, Inc.
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors. The company's preclinical candidates include those targeting influenza A and B antibodies and antibody drug conjugates, and coronavirus monoclonal antibodies; and PRO-XTEN, a dual-masked TCEs targeting variety of solid tumors. It has grant collaboration and license agreement with Astellas; license agreement with Norgine for the treatment of CHD; amended and restated letter agreement with the Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreement with the Institute for Research in Biomedicine; a license agreement with The Rockefeller University; license agreements with Xencor; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.
Vir Biotechnology, Inc. — frequently asked questions
What is Vir Biotechnology, Inc.'s revenue?
Vir Biotechnology, Inc. (VIR) reported revenue of $68.56M for fiscal year 2025, down 7.6% from the prior year, according to its SEC filings.
Is Vir Biotechnology, Inc. profitable?
No — VIR reported a net loss of $-437.99M in fiscal 2025.
What is VIR's P/E ratio?
Vir Biotechnology, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How fast is Vir Biotechnology, Inc. growing?
VIR's revenue grew at roughly -2.1% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Vir Biotechnology, Inc. have?
As of fiscal year 2025, VIR carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Vir Biotechnology, Inc.'s gross margin?
VIR's gross margin was 100.0% in fiscal 2025 — gross profit of $68.53M on revenue of $68.56M.
What is Vir Biotechnology, Inc.'s market cap?
Vir Biotechnology, Inc. (VIR) has a market capitalization of about $1.38B, based on the latest data in our nightly-refreshed cache.
When does Vir Biotechnology, Inc.'s fiscal year end?
VIR's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Vir Biotechnology, Inc.'s official SEC filings (10-K and 10-Q), covering 9 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.